The last year (and particularly the last few months) of the Biden Administration brought a flurry of activity from the Federal Trade Commission ...

BLCO may be sold in 2025 to service the debt of majority shareholder BHC, and any sale will be at a premium to the current ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

AbbVie is using innovative technologies like AI, wearables and automation to speed up drug discovery, clinical trials, and ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...

Feb 7 (Reuters) - AbbVie (ABBV.N), opens new tab said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections, including those caused by ...

AbbVie Inc. (NYSE:ABBV) showed positive top-line growth from its immunosuppressive drugs, Skyrizi and Rinvoq. Abbvie’s management continues to work through the loss of exclusivity from Humira ...

Like AbbVie’s duo, Novo Nordisk’s pair of GLP-1 meds also saw their TV ad spending slip in January. Each of the drugs fell three spots from their December seats: Obesity-focused Wegovy took ...

It can occur with prescription or nonprescription drugs. It can also range from mild to severe. Substance use disorder, formerly known as “drug abuse,” develops when substance use interferes ...

AbbVie Inc. ABBV reported fourth-quarter 2024 ... Revenues in the fourth quarter were driven by robust sales of key drugs Rinvoq, Skyrizi, Venclexta and Vraylar, coupled with significant ...

AbbVie’s oncology/hematology sales rose 12.9% to $1.69 billion in the quarter, as sales from the recently acquired ovarian cancer drug Elahere and rising Venclexta sales more than offset the ...